LX3010 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

87 results for “LX3010”

Trials

View all 51 →

A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

150 participants · First posted Feb 26, 2024

HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors

150 participants · First posted Nov 1, 2021

A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma

30 participants · First posted May 25, 2022

Drugs

View all 30 →

Investigational

KD3010

C₃₀H₃₃F₃N₂O₈S₂

EX1010

ZX2010

News

Lexeo to Acquire Mantle Therapeutics for Up to $21.3M, Adding Four Frataxin-Targeting FA Programs

Lumosa's LT3001 Shows Functional Improvements in Phase 2 Trials for Acute Ischemic Stroke

Lumosa Therapeutics' LT3001 Shows Promise in Phase II Acute Ischemic Stroke Trial

Page 1 of 9